AHL
AXSM icon

Abel Hall LLC’s Axsome Therapeutics AXSM Stock Holding History

Abel Hall LLC’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Buy
1,203
+34
+3% +$5.87K 0.04% 621
2025
Q4 		$214K Buy
+1,169
New +$163K 0.05% 508

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Abel Hall LLC's AXSM Position: Q1 2026 in Review

Abel Hall LLC increased its Axsome Therapeutics (AXSM) stake by 2.9% in Q1 2026, buying an estimated $5.87K and bringing the position to 1,203 shares worth $203K. The position accounts for 0.04% of the portfolio, ranked #621.

Abel Hall LLC first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $214K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Abel Hall LLC held 1,203 shares of Axsome Therapeutics worth $203K as of Q1 2026.
  • Abel Hall LLC bought 34 Axsome Therapeutics shares in Q1 2026, an estimated $5.87K.
  • Axsome Therapeutics made up 0.04% of Abel Hall LLC's portfolio in Q1 2026, its #621 holding.
  • Abel Hall LLC first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Abel Hall LLC's Axsome Therapeutics position peaked at $214K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.